Beginning a New Era of Precision Alzheimer's Therapeutics

Lecanemab in Early Alzheimer's Disease— NEJM , Jan 2023 www.nejm.org/ doi/10.1056/NEJMoa2212948

Roche's Genentech returns Alzheimer's assets to AC Immune, cutting 18-year tie to the biotech— Fierce Biotech , Jan 2024 www.fiercebiotech.com/biotech/roches-genentech-returns-alzheimers-assets-ac-immune-cutting-18-year-tie-biotech

FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval—FDA website, Jul 2023 www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval

FDA's Decision to Approve New Treatment for Alzheimer's Disease—FDA website, Jul 2021 www.fda.gov/drugs/our-perspective/fdas-decision-approve-new-treatment-alzheimers-disease

Aduhelm Phase 3 Data: ARIA Is Common, Sometimes Serious—Alzforum website, Dec 2021 www.alzforum.org/news/research-news/aduhelm-phase-3-data-aria-common-sometimes-serious

Biogen Will Refocus Its Alzheimer's Pipeline and Stop Selling Aduhelm— Inside Precision Medicine , Jan 2024 www.insideprecisionmedicine.com/topics/patient-care/biogen-will-refocus-its-alzheimers-pipeline-and-stop-selling-aduhelm/

Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease—Eli Lilly website, May 2023 www.investor. lilly.com/news-releases/news-release-details/lillys-donanemab-significantly-slowed-cognitive-and-functional

Donanemab in Early Symptomatic Alzheimer Disease The TRAILBLAZER-ALZ 2 Randomized Clinical Trial— JAMA , July 17, 2023 www.jamanetwork.com/journals/jama/fullarticle/2807533?s=4

Acumen's stock surges as early Alzheimer's data suggest next-gen Leqembi rival is active— Fierce Biotech , July 2023 www.fiercebiotech.com/biotech/acumen-surges-early-alzheimers-data-suggest-next-gen-leqembi-rival-active

Apolipoprotein E and Alzheimer disease: risk, mechanisms, and therapy— Nature Reviews Neurology , Feb 2013 www.ncbi.nlm.nih.gov/pmc/articles/PMC3726719/

ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies— Molecular Neurodegeneration , Nov 2022 www.molecularneurodegeneration.biomedcentral.com/articles/10.1186/s13024-022-00574-4

Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer's disease— Nature Neuroscience , Mar 2019 www.nature.com/articles/s41593-018-0332-9

Biomarker Changes during 20 Years Preceding Alzheimer's Disease— NEJM , Feb 2024 www.nejm.org/doi/full/10.1056/NEJMoa2310168